Dermira Inc. (DERM) Given Positive Rating at Needham & Company LLC
Separately, Zacks Investment Research raised Dermira from a sell rating to a hold rating in a research note on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Dermira presently has a consensus rating of Buy and an average price target of $41.00.
Shares of Dermira (NASDAQ:DERM) opened at 34.97 on Monday. The firm has a 50-day moving average price of $32.92 and a 200 day moving average price of $29.32. The company’s market cap is $1.24 billion. Dermira has a 1-year low of $17.42 and a 1-year high of $36.16.
Dermira (NASDAQ:DERM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by $0.03. On average, equities analysts anticipate that Dermira will post ($3.39) earnings per share for the current year.
In related news, VP Christopher M. Griffith sold 1,303 shares of the firm’s stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $30.02, for a total transaction of $39,116.06. Following the completion of the sale, the vice president now owns 44,941 shares of the company’s stock, valued at $1,349,128.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The stock was sold at an average price of $35.01, for a total value of $525,150.00. Following the sale, the chief financial officer now directly owns 20,116 shares of the company’s stock, valued at approximately $704,261.16. The disclosure for this sale can be found here. Corporate insiders own 17.30% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in shares of Dermira by 6,034.5% in the second quarter. JPMorgan Chase & Co. now owns 3,558 shares of the biopharmaceutical company’s stock valued at $104,000 after buying an additional 3,500 shares during the last quarter. Glenmede Trust Co. NA purchased a new position in shares of Dermira during the second quarter valued at about $170,000. A.R.T. Advisors LLC purchased a new position in shares of Dermira during the second quarter valued at about $207,000. DIAM Co. Ltd. purchased a new position in shares of Dermira during the second quarter valued at about $231,000. Finally, Prudential Financial Inc. purchased a new position in shares of Dermira during the second quarter valued at about $253,000. 82.46% of the stock is owned by institutional investors and hedge funds.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.